Klotho Protein as a Topical Therapy for Facial Photoaging Using Combined Delivery Technologies.

Background: Klotho, a protein linked to longevity, influences oxidative stress and cellular balance, promoting antiaging effects in the skin. In vitro, Klotho reduced ultraviolet A-induced oxidative DNA damage and increased human telomerase reverse transcriptase and Sirtuin 6, supporting further evaluation. This study evaluates whether the combined use of 3 Klotho products (face serum 25%, eye serum 15%, night cream 10%) produces synergistic improvements in visible photoaging. Methods: This is an open-label, single-arm, 16-week study involving adults aged 25-75 years, with Fitzpatrick skin types I-IV and mild to severe facial photodamage. Participants applied the 3-product regimen. The primary endpoint was the change from baseline to week 16 on a specified clinical photodamage scale. Secondary endpoints included dyschromia, erythema, dryness/scaling, peeling, lines/wrinkles, and atrophy. An exploratory item assessed perceived hydration. Safety data included adverse events and local reactions. Results: Facial photodamage showed significant improvement at week 16 with an average reduction of 48.0% from baseline ( Conclusions: The 3-product Klotho regimen was well tolerated and showed early, progressive improvements in photodamage during the 16-week study. Our findings suggest that topical Klotho may benefit multiple aspects of photoaging.